<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35412843</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>12</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1557-9042</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2022</Year>
              <Month>Apr</Month>
              <Day>12</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of neurotrauma</Title>
          <ISOAbbreviation>J Neurotrauma</ISOAbbreviation>
        </Journal>
        <ArticleTitle>DREADD-mediated activation of the locus coeruleus restores descending nociceptive inhibition after traumatic brain injury in rats.</ArticleTitle>
        <ELocationID EIdType="doi" ValidYN="Y">10.1089/neu.2021.0485</ELocationID>
        <Abstract>
          <AbstractText>Disruption of endogenous pain control mechanisms including descending pain inhibition has been linked to several forms of pain including chronic pain after traumatic brain injury (TBI). The locus coeruleus (LC) is the principal noradrenergic (NA) nucleus participating in descending pain inhibition. We therefore hypothesized that selectively stimulating LC neurons would reduce nociception after TBI. All experiments used a well-characterized rat lateral fluid percussion model of TBI. NA neurons were stimulated by administering clozapine N-oxide (CNO) to rats selectively expressing a Designer Receptor Exclusively Activated by Designer Drug (DREADD) viral construct in their LC's. Mechanical nociceptive thresholds were measured using von Frey fibers. The efficacy of diffuse noxious inhibitory control (DNIC), a critical endogenous pain control mechanism, was assessed using the hindpaw administration of capsaicin. Immunohistochemical analyses demonstrated the selective expression of the DREADD construct in LC neurons after stereotactic injection. During the first week after TBI, when rats demonstrated hindlimb nociceptive sensitization, CNO administration provided transient anti-nociception in DREADD-expressing rats but not in rats injected with control virus. Seven weeks after TBI we observed a complete loss of DNIC in response to capsaicin. However, CNO administration largely restored DNIC in TBI DREADD-expressing rats but not those injected with control virus. Unexpectedly, the effects of LC activation in the DREADD-expressing rats were blocked by the α-1 adrenergic receptor antagonist, prazosin but not the α-2 adrenergic receptor antagonist, atipamezole. These results suggest that directly stimulating the LC after TBI can reduce both early and late manifestations of dysfunctional endogenous pain regulation. Clinical approaches to activating descending pain circuits may reduce suffering in those with pain after TBI.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Irvine</LastName>
            <ForeName>Karen-Amanda</ForeName>
            <Initials>KA</Initials>
            <AffiliationInfo>
              <Affiliation>Palo Alto VA Medical Center, 19977, Anesthesia service, Palo Alto, California, United States.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Stanford Medicine, 158423, Anesthesiology, Perioperative and Pain Medicine, Stanford, California, United States; kairvine@stanford.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Peters</LastName>
            <ForeName>Christopher M</ForeName>
            <Initials>CM</Initials>
            <AffiliationInfo>
              <Affiliation>Wake Forest Baptist Medical Center, 12280, Anesthesiology, Winston-Salem, North Carolina, United States; chrpeter@wakehealth.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vazey</LastName>
            <ForeName>Elena M</ForeName>
            <Initials>EM</Initials>
            <AffiliationInfo>
              <Affiliation>University of Massachusetts Amherst, 14707, Biology, Amherst, Massachusetts, United States; evazey@umass.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ferguson</LastName>
            <ForeName>Adam R</ForeName>
            <Initials>AR</Initials>
            <AffiliationInfo>
              <Affiliation>University of California San Francisco, 8785, Brain and Spinal Injury Center, Dept Neurosurgery, San Francisco, California, United States.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>San Francisco VA Health Care System, 19980, San Francisco, California, United States; adam.ferguson@ucsf.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Clark</LastName>
            <ForeName>David</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Palo Alto VA Medical Center, 19977, Anesthesiology Service, Palo Alto, California, United States.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Stanford Medicine, 158423, Anesthesiology, Perioperative and Pain Medicine, Stanford, California, United States; djclark@stanford.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>12</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Neurotrauma</MedlineTA>
        <NlmUniqueID>8811626</NlmUniqueID>
        <ISSNLinking>0897-7151</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">ANIMAL STUDIES</Keyword>
        <Keyword MajorTopicYN="N">BEHAVIORAL ASSESSMENTS</Keyword>
        <Keyword MajorTopicYN="N">NEUROTRANSMITTERS</Keyword>
        <Keyword MajorTopicYN="N">RECOVERY</Keyword>
        <Keyword MajorTopicYN="N">TRAUMATIC BRAIN INJURY</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>12</Day>
          <Hour>17</Hour>
          <Minute>11</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35412843</ArticleId>
        <ArticleId IdType="doi">10.1089/neu.2021.0485</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
